Literature DB >> 20886194

Cysteine residues in CUB-1 domain are critical for ADAMTS13 secretion and stability.

Zhou Zhou1, Hui-Chun Yeh, Hua Jing, Christina Wang, Zhenyin Tao, Huiwan Choi, Khatira Aboulfatova, Renhai Li, Jing-Fei Dong.   

Abstract

Upon stimulation, endothelial cells release von Willebrand factor (VWF) enriched in ultra-large (UL) forms that are rapidly cleaved by ADAMTS13. The zinc metalloprotease fits in the consensus for members of the ADAMTS family, but also contains two unique C-terminal CUB domains. There are five and two cysteine residues in the CUB-1 and CUB-2 domains, respectively, instead of four as deducted from the consensus. In this study, we investigated the role of cysteine residues in the CUB-1 domain in ADAMTS13 synthesis and activity. CUB-1 and cysteine mutations were expressed in mammalian cell lines and examined for synthesis, secretion, stability, and VWF-cleaving activity. When expressed as an isolated domain, CUB-1, but not CUB-2, covalently aggregated. Converting any of the four cysteines that fit in the CUB consensus (C1192, C1213, C1236 and C1254) reduced the secretion of the mutants to the conditioned medium, but not to extracellular matrix. The mutations also resulted in a moderate increase in proteolytic degradation and decrease in cleaving VWF under static, but not flowing conditions. In contrast, replacing C1275, which was found to be in the thiol form, with a serine residue prevented covalent aggregation of CUB-1, but had no effect on secretion and VWF-cleaving activity. C1275S was also markedly resistant to proteolytic degradation. The data illustrate the importance of consensus cysteines in the secretion and proteolytic activity of ADAMTS13. They also identify an ADAMTS-13 mutant that is resistant to proteolytic degradation, while maintaining a normal VWF-cleaving activity.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20886194      PMCID: PMC5649353          DOI: 10.1160/TH10-07-0446

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  29 in total

1.  Novel ADAMTS-13 mutations in an adult with delayed onset thrombotic thrombocytopenic purpura.

Authors:  Z Tao; K Anthony; Y Peng; H Choi; L Nolasco; L Rice; J L Moake; J-F Dong
Journal:  J Thromb Haemost       Date:  2006-06-22       Impact factor: 5.824

2.  The cytoplasmic domain of glycoprotein (GP) Ibalpha constrains the lateral diffusion of the GP Ib-IX complex and modulates von Willebrand factor binding.

Authors:  J F Dong; C Q Li; G Sae-Tung; W Hyun; V Afshar-Kharghan; J A López
Journal:  Biochemistry       Date:  1997-10-14       Impact factor: 3.162

3.  Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura.

Authors:  X Zheng; D Chung; T K Takayama; E M Majerus; J E Sadler; K Fujikawa
Journal:  J Biol Chem       Date:  2001-09-13       Impact factor: 5.157

4.  The CUB domain. A widespread module in developmentally regulated proteins.

Authors:  P Bork; G Beckmann
Journal:  J Mol Biol       Date:  1993-05-20       Impact factor: 5.469

5.  Binding of ADAMTS13 to von Willebrand factor.

Authors:  Elaine M Majerus; Patricia J Anderson; J Evan Sadler
Journal:  J Biol Chem       Date:  2005-04-11       Impact factor: 5.157

6.  Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura.

Authors:  G G Levy; W C Nichols; E C Lian; T Foroud; J N McClintick; B M McGee; A Y Yang; D R Siemieniak; K R Stark; R Gruppo; R Sarode; S B Shurin; V Chandrasekaran; S P Stabler; H Sabio; E E Bouhassira; J D Upshaw; D Ginsburg; H M Tsai
Journal:  Nature       Date:  2001-10-04       Impact factor: 49.962

7.  Cleavage of the ADAMTS13 propeptide is not required for protease activity.

Authors:  Elaine M Majerus; Xinglong Zheng; Elodee A Tuley; J Evan Sadler
Journal:  J Biol Chem       Date:  2003-09-15       Impact factor: 5.157

8.  Two novel ADAMTS13 gene mutations in thrombotic thrombocytopenic purpura/hemolytic-uremic syndrome (TTP/HUS).

Authors:  Christoph Licht; Ludwig Stapenhorst; Thorsten Simon; Ulrich Budde; Reinhard Schneppenheim; Bernd Hoppe
Journal:  Kidney Int       Date:  2004-09       Impact factor: 10.612

9.  Mutation analysis and clinical implications of von Willebrand factor-cleaving protease deficiency.

Authors:  Karin Assink; Rikke Schiphorst; Sarah Allford; Diana Karpman; Amos Etzioni; Bénédicte Brichard; Nicole van de Kar; Leo Monnens; Lambertus van den Heuvel
Journal:  Kidney Int       Date:  2003-06       Impact factor: 10.612

10.  The cooperative activity between the carboxyl-terminal TSP1 repeats and the CUB domains of ADAMTS13 is crucial for recognition of von Willebrand factor under flow.

Authors:  Ping Zhang; Weilan Pan; Ann H Rux; Bruce S Sachais; X Long Zheng
Journal:  Blood       Date:  2007-05-31       Impact factor: 22.113

View more
  7 in total

1.  ADAMTS13 missense variants associated with defective activity and secretion of ADAMTS13 in a patient with non-cirrhotic portal hypertension.

Authors:  Ashish Goel; V Raghupathy; G J Amirtharaj; Aaron Chapla; Aparna Venkatraman; Banumathi Ramakrishna; Anup Ramachandran; Nihal Thomas; K A Balasubramanian; Ian Mackie; Elwyn Elias; Chundamannil E Eapen
Journal:  Indian J Gastroenterol       Date:  2017-10-05

2.  Residual plasmatic activity of ADAMTS13 is correlated with phenotype severity in congenital thrombotic thrombocytopenic purpura.

Authors:  Luca A Lotta; Haifeng M Wu; Ian J Mackie; Marina Noris; Agnes Veyradier; Marie A Scully; Giuseppe Remuzzi; Paul Coppo; Ri Liesner; Roberta Donadelli; Chantal Loirat; Richard A Gibbs; April Horne; Shangbin Yang; Isabella Garagiola; Khaled M Musallam; Flora Peyvandi
Journal:  Blood       Date:  2012-04-23       Impact factor: 22.113

3.  Solving the Measurement Problem and then Steppin' Out over the Line Riding the Rarest Italian: Crossing the Streams to Retrieve Stable Bioactivity in Majorana Bound States of Dialy zed Human Platelet Lysates.

Authors:  Mark Roedersheimer
Journal:  Open Neurol J       Date:  2015-06-26

4.  Novel mutations in ADAMTS13 CUB domains cause abnormal pre-mRNA splicing and defective secretion of ADAMTS13.

Authors:  Yizhi Jiang; Dongping Huang; Yuji Kondo; Miao Jiang; Zhenni Ma; Lu Zhou; Jian Su; Xia Bai; Changgeng Ruan; Zhaoyue Wang; Lijun Xia
Journal:  J Cell Mol Med       Date:  2020-02-19       Impact factor: 5.310

5.  C1R Mutations Trigger Constitutive Complement 1 Activation in Periodontal Ehlers-Danlos Syndrome.

Authors:  Rebekka Gröbner; Ines Kapferer-Seebacher; Albert Amberger; Rita Redolfi; Fabien Dalonneau; Erik Björck; Di Milnes; Isabelle Bally; Veronique Rossi; Nicole Thielens; Heribert Stoiber; Christine Gaboriaud; Johannes Zschocke
Journal:  Front Immunol       Date:  2019-11-05       Impact factor: 7.561

6.  Identification of cysteine thiol-based linkages in ADAMTS13 in support of a non-proteolytic regulation of von Willebrand factor.

Authors:  Hanspeter Rottensteiner; Birgit K Seyfried; Stefan Kaufmann; Christian Fiedler; Jing-Fei Dong; X Long Zheng; Barbara Plaimauer; Friedrich Scheiflinger
Journal:  J Thromb Haemost       Date:  2019-09-03       Impact factor: 5.824

7.  Crystal structure of ADAMTS13 CUB domains reveals their role in global latency.

Authors:  H J Kim; Y Xu; A Petri; K Vanhoorelbeke; J T B Crawley; J Emsley
Journal:  Sci Adv       Date:  2021-04-16       Impact factor: 14.136

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.